Juno Therapeutics Presents at American Society of Hematology


 
 
03:05 12/09/2017

Seattle based Juno Therapeutics, Inc.JUNO  today presented new translational insights on clinical outcomes with its investigational CAR T product candidate JCAR017 at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.

The company also announced that JCAR017, a defined composition CD19-directed CAR T cell product candidate using a 4-1BB costimulatory domain, had received the United States Adopted Name lisocabtagene maraleucel (liso-cel).

"Today’s presentations suggest that the defined composition of JCAR017 supports a potential best-in-class clinical profile and helps to unlock key translational insights,” said Sunil Agarwal, M.D., Juno's President of Research and Development.

Results from these exploratory analyses suggest that patient factors may impact safety and efficacy for DLBCL patients. These factors included:

•Baseline patient characteristics, including high tumor burden and markers of inflammation, were associated with high CAR T cell expansion and increased rates of cytokine release syndrome (CRS) and neurotoxicity (NT).

•Data showed an approximately 8-fold increased risk for CRS and NT in patients with high baseline tumor burden.



•Baseline markers of inflammation were associated with more durable responses; with respect to tumor burden the association was less pronounced.



Three days ago Juno announced three license agreements to advance its program in multiple myeloma using gamma secretase inhibitors (GSIs) in combination with BCMA-directed CAR T cells.

Through its agreement with Eli Lilly and Company, Juno will acquire a license to the GSI known as LY3039478, a product candidate that has been studied in 411 patients and healthy volunteers. Through its agreements with OncoTracker and Fred Hutchinson Cancer Research Center, Juno will gain exclusive rights to intellectual property within the field of combinations of GSIs and BCMA-directed engineered T cells.


This article has been provided by a Chasing Markets contributor. All content submitted by this author represent their personal opinions, and should be considered as such for entertainment purpose only. All opinions expressed are those of the writer, and may not necessarily represent fact, opinions, or bias of Chasing Markets.
Most Read